A Study Evaluating Venetoclax Alone and in Combination With Azacitidine in Participants With Relapsed/Refractory Myelodysplastic Syndromes (MDS)
Public ClinicalTrials.gov record NCT02966782. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1b Study Evaluating the Safety and Pharmacokinetics of Venetoclax as a Single-Agent and in Combination With Azacitidine in Subjects With Relapsed/Refractory Myelodysplastic Syndromes
Study identification
- NCT ID
- NCT02966782
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1
- Lead sponsor
- AbbVie
- Industry
- Enrollment
- 70 participants
Conditions and interventions
Conditions
Interventions
- venetoclax Drug
- azacitidine Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 6, 2017
- Primary completion
- Apr 4, 2023
- Completion
- Apr 4, 2023
- Last update posted
- May 8, 2023
2017 – 2023
United States locations
- U.S. sites
- 10
- U.S. states
- 8
- U.S. cities
- 9
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Arizona Cancer Center - North Campus /ID# 157503 | Tucson | Arizona | 85719-1478 | — |
| University of Colorado Hospital /ID# 155365 | Aurora | Colorado | 80045 | — |
| Yale University /ID# 162544 | New Haven | Connecticut | 06510 | — |
| Duplicate_University of Chicago /ID# 155364 | Chicago | Illinois | 60637 | — |
| Pediatric Endocrine Associates /ID# 171227 | Boston | Massachusetts | 02114 | — |
| Dana-Farber Cancer Institute /ID# 155361 | Boston | Massachusetts | 02215 | — |
| University of Massachusetts - Worcester /ID# 155366 | Worcester | Massachusetts | 01655 | — |
| Columbia Univ Medical Center /ID# 156388 | New York | New York | 10032-3725 | — |
| Oregon Health and Science University /ID# 155360 | Portland | Oregon | 97239 | — |
| University of Texas MD Anderson Cancer Center /ID# 155362 | Houston | Texas | 77030 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 13 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02966782, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 8, 2023 · Synced Jul 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02966782 live on ClinicalTrials.gov.